Teriparatide Acetate
No CAS. 52232-67-4
Molecular Formula C181H291N55O51S2
Peso molecular 41177.72
Pureza (HPLC: Ge; 98.5%
Appearance White powder
Used: APIs , postmenopausal women with osteoporosis;Protected amino acids; péptidos
Aplicaciones &Fuction
Teriparatide is indicated for use in postmenopausal women with osteoporosis at a high risk for fracture or with a history of ostoporotic fracture, pacientes con múltiples factores de riesgo de fractura, y para pacientes que han fracasado o son intolerantes a otras terapias disponibles para la osteoporosis.
Teriparatide is also indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk of fracture, pacientes con múltiples factores de riesgo de fractura, y para pacientes que han fracasado o son intolerantes a otras terapias disponibles para la osteoporosis.
Teriparatide is indicated as well for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy.
Teriparatide should not be prescribed for patients who are at increased risks for osteosarcoma. This includes those with Paget’s Disease of bone or unexplained elevations of serum alkaline phosphate, open epiphysis, or prior radiation therapy involving the skeleton.
